Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 3/20 | 1.00 |
| ▸ | TFEB | P19484 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 0.84 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.84 |
| ▸ | NPC1 | O15118 | 3/20 | 0.84 |
| ▸ | RAB9A | P51151 | 2/20 | 0.84 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.84 |
| ▸ | ATM | Q13315 | 1/20 | 0.84 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.84 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.84 |
| ▸ | LY96 | Q9Y6Y9 | 2/20 | 0.81 |
| ▸ | LMNA | P02545 | 2/20 | 0.70 |
| ▸ | BCHE | P06276 | 1/20 | 0.70 |
| ▸ | HPGD | P15428 | 4/20 | 0.67 |
| ▸ | MAOB | P27338 | 3/20 | 0.64 |
| ▸ | AR | P10275 | 1/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.62 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.62 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16403662 | 1.00 | NFE2L2 (1.00) | NFE2L2TFEBMAPTKDM4ENPC1 | |
| SCHEMBL2744047 | 1.00 | NFE2L2 (1.00) | NFE2L2TFEBMAPTKDM4ENPC1 | |
| SCHEMBL30307386 | 1.00 | NFE2L2 (1.00) | NFE2L2TFEBMAPTKDM4ENPC1 | |
| SCHEMBL29805195 | 1.00 | NFE2L2 (1.00) | NFE2L2TFEBMAPTKDM4ENPC1 | |
| SCHEMBL28360791 | 0.92 | MAPT (1.00) | NFE2L2TFEBMAPTKDM4ENPC1 | |
| SCHEMBL16093028 | 0.92 | NFE2L2 (0.84) | NFE2L2TFEBMAPTKDM4ENPC1 | |
| SCHEMBL27034286 | 0.90 | NFE2L2 (0.81) | NFE2L2TFEBMAPTKDM4ENPC1 | |
| SCHEMBL609604 | 0.88 | NFE2L2 (0.78) | NFE2L2TFEBMAPTKDM4ENPC1 | |
| SCHEMBL609603 | 0.88 | NFE2L2 (0.78) | NFE2L2TFEBMAPTKDM4ENPC1 | |
| SCHEMBL28356941 | 0.87 | NFE2L2 (0.77) | NFE2L2TFEBMAPTKDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116172991-A | Application of RPN77612 in preparation of medicine for treating altitude cerebral edema | 南通大学 | 2023-05-30 | — | — | CN | claimed |
| US-9540299-B2 | MTOR-independent activator of TFEB for autophagy enhancement and uses thereof | HONG KONG BAPTIST UNIVERSITY (HK) | 2017-01-10 | — | — | US | claimed |
| US-20160221907-A1 | MTOR-independent activator of TFEB for autophagy enhancement and uses thereof | HONG KONG BAPTIST UNIVERSITY (CN) | 2016-08-04 | — | — | US | claimed |
| US-20100152493-A1 | BIS(ARYLMETHYLIDENE)ACETONE COMPOUND, ANTI-CANCER AGENT, CARCINOGENESIS-PREVENTIVE AGENT, INHIBITOR OF EXPRESSION OF Ki-Ras, ErbB2, c-Myc AND CYCLINE D1, BETA-CATENIN-DEGRADING AGENT, AND p53 EXPRESSION ENHANCER | SHIBATA, HIROYUKI (JP) | 2010-06-17 | — | — | US | claimed |
| CN-116172991-A | Application of RPN77612 in preparation of medicine for treating altitude cerebral edema | 南通大学 | 2023-05-30 | — | — | CN | disclosed |
| CN-116172991-A | Application of RPN77612 in preparation of medicine for treating altitude cerebral edema | 南通大学 | 2023-05-30 | — | — | CN | disclosed |
| CN-116172991-A | Application of RPN77612 in preparation of medicine for treating altitude cerebral edema | 南通大学 | 2023-05-30 | — | — | CN | disclosed |
| US-20220152001-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2022-05-19 | — | — | US | disclosed |
| US-20220023172-A1 | COSMETIC COMPOSITIONS AND METHODS OF USE | TRUJILLO KRISTINA (US) | 2022-01-27 | — | — | US | disclosed |
| US-20220000804-A1 | INTRANASAL NANO INDUCER FOR PREVENTING AND TREATING NEURODEGENERATIVE DISEASES AND METHOD THEREOF | NASAL-PHYTO (SZ) PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2022-01-06 | — | — | US | disclosed |
| US-10987319-B2 | TFEB activator C1 ameliorates app and tau pathology and rescues cognitive deficits in neurodegenerative diseases | HONG KONG BAPTIST UNIVERSITY (HK) | 2021-04-27 | — | — | US | disclosed |
| US-10987319-B2 | TFEB activator C1 ameliorates app and tau pathology and rescues cognitive deficits in neurodegenerative diseases | HONG KONG BAPTIST UNIVERSITY (HK) | 2021-04-27 | — | — | US | disclosed |
| US-8841326-B2 | Therapeutic curcumin derivatives | STC.UNM (US) | 2014-09-23 | — | — | US | disclosed |
| US-8178727-B2 | Bis(arylmethylidene)acetone compound, anti-cancer agent, carcinogenesis-preventive agent, inhibitor of expression of Ki-Ras, ErbB2, c-Myc and Cycline D1, β-catenin-degrading agent, and p53 expression enhancer | NATIONAL UNIVERSITY CORPORATION TOHOKU UNIVERSITY (JP) | 2012-05-15 | — | — | US | disclosed |
| US-20100152493-A1 | BIS(ARYLMETHYLIDENE)ACETONE COMPOUND, ANTI-CANCER AGENT, CARCINOGENESIS-PREVENTIVE AGENT, INHIBITOR OF EXPRESSION OF Ki-Ras, ErbB2, c-Myc AND CYCLINE D1, BETA-CATENIN-DEGRADING AGENT, AND p53 EXPRESSION ENHANCER | SHIBATA, HIROYUKI (JP) | 2010-06-17 | — | — | US | disclosed |
| US-20070060644-A1 | Therapeutic curcumin derivatives | STC.UNM | 2007-03-15 | — | — | US | disclosed |
| US-20070060644-A1 | Therapeutic curcumin derivatives | STC.UNM | 2007-03-15 | — | — | US | disclosed |
| US-20070060644-A1 | Therapeutic curcumin derivatives | STC.UNM | 2007-03-15 | — | — | US | disclosed |
| US-20060276536-A1 | Cancer treatment using curcumin derivatives | STC.UNM | 2006-12-07 | — | — | US | disclosed |
| US-20050069551-A1 | Cytotoxic compound-protein conjugates as suppressors of tumor growth and angiogenesis | EMORY UNIVERSITY | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152493-A1 | BIS(ARYLMETHYLIDENE)ACETONE COMPOUND, ANTI-CANCER AGENT, CARCINOGENESIS-PREVENTIVE AGENT, INHIBITOR OF EXPRESSION OF Ki-Ras, ErbB2, c-Myc AND CYCLINE D1, BETA-CATENIN-DEGRADING AGENT, AND p53 EXPRESSION ENHANCER | MYC, CCNE2, CCNE1 | NFE2L2 109/4885TFEB 293/4885MAPT 3668/4885 |
| US-20070060644-A1 | Therapeutic curcumin derivatives | FABP2, GLS2, FABP1 | NFE2L2 75/4885TFEB 19/4885MAPT 448/4885 |
| US-20220023172-A1 | COSMETIC COMPOSITIONS AND METHODS OF USE | NFKBIA, IKBKB, NFKB2 | NFE2L2 9/4885TFEB 33/4885MAPT 2616/4885 |
| US-10987319-B2 | TFEB activator C1 ameliorates app and tau pathology and rescues cognitive deficits in neurodegenerative diseases | TFEB, PSEN1, MAPT | NFE2L2 2183/4885TFEB 1/4885MAPT 3/4885 |
| US-20220000804-A1 | INTRANASAL NANO INDUCER FOR PREVENTING AND TREATING NEURODEGENERATIVE DISEASES AND METHOD THEREOF | BECN1, SQSTM1, ATG13 | NFE2L2 593/4885TFEB 7/4885MAPT 14/4885 |
| US-20220152001-A1 | HUMAN THERAPEUTIC AGENTS | INMT, HNMT, HASPIN | NFE2L2 832/4885TFEB 414/4885MAPT 497/4885 |
| US-20050069551-A1 | Cytotoxic compound-protein conjugates as suppressors of tumor growth and angiogenesis | VEGFA, AGER, HDGF | NFE2L2 896/4885TFEB 357/4885MAPT 563/4885 |
| US-20160221907-A1 | MTOR-independent activator of TFEB for autophagy enhancement and uses thereof | TFEB, SQSTM1, ATG7 | NFE2L2 161/4885TFEB 1/4885MAPT 388/4885 |
| US-20060276536-A1 | Cancer treatment using curcumin derivatives | BRCA1, VHL, TP53 | NFE2L2 5/4885TFEB 346/4885MAPT 2066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.